ASTRO: Few PCPs Order Low-Dose CT for Lung CA Screening

Share this content:
ASTRO: Few PCPs Order Low-Dose CT for Lung CA Screening
ASTRO: Few PCPs Order Low-Dose CT for Lung CA Screening

(HealthDay News) -- Few primary care providers (PCPs) order low-dose computed tomography (LDCT) for lung cancer screening in patients at high risk, according to a study presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Oct. 30 to Nov. 1.

Jennifer Lewis, M.D., from the Wake Forest School of Medicine in Winston-Salem, N.C., and colleagues examined lung cancer screening use and potential barriers to LDCT use. Data were collected from surveys of 293 respondents.

The researchers found that few PCPs reported ordering lung cancer screening examinations (chest X-ray, 21 percent; LDCT, 12 percent; and sputum cytology, 3 percent). About half of providers (48 percent) knew at least three of the six guideline components for LDCT screening; one-quarter (24 percent) did not know any components. Providers who knew three or more components were more likely to order LDCT (odds ratio, 5.0). Thirty percent of providers reported being unsure of LDCT effectiveness in reducing cancer mortality, and these providers had not ordered LDCT. A majority of providers (80 percent) expressed interest in receiving more education about lung cancer screening. Patient cost, potential harm from false-positive findings and incidental findings, patients' lack of awareness, and no insurance coverage were reported as the most commonly perceived barriers to LDCT screening.

"The results of this survey highlight an essential need for provider education on the effectiveness of low-dose CT screening for lung cancer, on lung cancer screening guideline recommendations, and the potential benefits and harms of screening," Lewis said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »